Exome Asset Management’s Sage Therapeutics SAGE Stock Holding History

Exome Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-35,257	Closed	-$764K	–	70
2023 Q4	$764K	Buy	+35,257	New	+$699K	0.76%	39

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Exome Asset Management's SAGE Position: Q1 2024 in Review

Exome Asset Management sold out of Sage Therapeutics (SAGE) in Q1 2024, closing a stake of 35,257 shares — an estimated $764K sold.

Exome Asset Management first reported a position in SAGE in Q4 2023 and held it in 1 quarter. The position peaked at $764K in Q4 2023. 204 funds tracked by Wall St. Rank hold SAGE as of Q1 2024.

Exome Asset Management reported no remaining Sage Therapeutics position as of Q1 2024 after selling out during the quarter.
Exome Asset Management sold 35,257 Sage Therapeutics shares in Q1 2024, an estimated $764K.
Exome Asset Management first reported a position in Sage Therapeutics in Q4 2023 and held it in 1 quarter.
Exome Asset Management's Sage Therapeutics position peaked at $764K in Q4 2023.
204 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2024.

Based on Exome Asset Management's 13F filing for Q1 2024, filed 15 May 2024.